Xuanzhu Biotechnology introduced single-target AXL inhibitors and only one domestic company applied for clinical application

Article source: Medical Rubik's Cube Info

Author: Shi Bei

On September 24, Sihuan Pharmaceutical issued an announcement that its subsidiary Xuanzhu Biotechnology and SignalChem Life Sciences signed a cooperation and licensing agreement on the development and commercialization rights of the AXL inhibitor SLC-391 in Greater China

AXL is a member of the TAM family of tyrosine protein kinases (Tyro3, ​​AXL and Mer).

SLC-391 is an effective, highly selective, and oral small molecule AXL inhibitor.

Earlier, SignalChem has reached a cooperation with Merck, and the two parties jointly conducted an evaluation of the effectiveness of the combination of SLC-391 and Keytruda for the treatment of advanced NSCLC

In China, many companies are developing AXL multi-target kinase inhibitors, but only one company has introduced a single-target selective AXL inhibitor 3D-229 (AVB-500) from the American company Aravive for a total of 219 million US dollars.

The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the off-target toxicity caused by the low selectivity of multi-target AXL kinase inhibitors, the problem of tumor cell resistance and the low affinity of monoclonal antibodies, which is not enough to destroy The interaction problem between natural GAS6/AXL

Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC)

At present, clinical trials of AVB-500 for renal cell carcinoma and urothelial cancer are also underway, and have obtained fast track qualification granted by the FDA for platinum-resistant recurrent ovarian cancer indications.

Source: Aravive official website